Nitrazepam (Mogadon) is a prescription benzodiazepine for short-term severe insomnia under the reviewed UK tablet labels. Next-day impairment and dependence require a prescribing and stopping plan. Mogadon: prescribing information.
- Dependence and withdrawal can occur even with recommended doses and short use. MHRA: January 2026 warning.
- Long action can complicate withdrawal timing. Scotland: tailored benzodiazepine reduction.
- Combining nitrazepam with opioids can cause fatal breathing suppression. MHRA: opioids and benzodiazepines.
- Do not suddenly stop an established prescription or copy an internet taper. NICE NG215: withdrawal care.
- Suspected benzodiazepine overdose requires immediate emergency help. MHRA: benzodiazepine patient resource.
- English prescription-item counts do not show unique patients, global rank or benefit. NHSBSA: nitrazepam item count.
Table of contents
- Evidence summary
- What nitrazepam is: Mogadon, tablets and severe adult insomnia
- How it works: GABA-A signalling, long action and morning impairment
- Insomnia care before a hypnotic: assessment, CBT and a review plan
- Supplements and practical support: avoid adding a sedating sleep stack
- What the evidence establishes: short trials and the January 2026 warning
- Risks and urgent symptoms: sedation, overdose, allergy and behaviour changes
- Interactions: opioids, alcohol, antihistamines, other sedatives and herbs
- Who needs extra assessment: sleep apnoea, organ disease, pregnancy and breastfeeding
- Clinician-led use and stopping: course limits, missed doses and flexible withdrawal
- Animal and laboratory evidence: mechanisms do not establish a personal regimen
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Adult severe-insomnia use | UK product-specific prescribing context | Maker-issued labels | Short course; no worldwide licensing claim. |
| Long-term comparative benefit | Historical small-trial abstract inspected | Exact sponsorship unclosed | No independent efficacy verdict. |
| Dependence and withdrawal | January 2026 MHRA review and NICE context | Industry-fee/source chains disclosed | Individual care; no forced rapid taper. |
| Breastfeeding | Maker leaflet and dated SPS context | Very limited underlying evidence | Specialist assessment, not blanket permission. |
| Supplements | Public safety/uncertainty context | Trial/contributor chains unclosed | No replacement or safe sleep stack established. |
| Prescribing frequency | Original English item-count table | Public authority route disclosed | Not patients, global rank or benefit. |
What nitrazepam is: Mogadon, tablets and severe adult insomnia
Accord’s reviewed product is a prescription 5 mg tablet. This is a formulation strength, not a personal dosing recommendation. Follow your own dispensing label; changing formulation requires pharmacist or prescriber advice. Accord: product identity and update.
Mogadon’s UK indication concerns severe, disabling or distressing insomnia where daytime sedation is acceptable. The licence does not establish worldwide approval or resolve the cause of insomnia. Mogadon: prescribing information.
England’s official 2025/26 table records 236,452 nitrazepam prescription items. This makes a dedicated guide useful; it does not make nitrazepam a preferred hypnotic. The chemical-level count combines repeat prescriptions and does not identify whether a prescription was for insomnia or another indication. NHSBSA: nitrazepam item count.
The dataset covers community dispensing in England, including hospital-issued prescriptions dispensed in the community. Hospital-pharmacy dispensing is excluded. An item is not a unique person or a measure of how much sleep improved. Comparisons with medicines mainly supplied in hospitals therefore need particular caution. NHSBSA: prescribing methodology.
Check the active ingredient on your own packet. A brand name, tablet appearance or familiar strength is not enough to confirm a change in formulation. Ask the pharmacist to explain any substitution and provide the corresponding current leaflet. This guide addresses adult insomnia care rather than a specialist childhood or epilepsy regimen.
How it works: GABA-A signalling, long action and morning impairment
Nitrazepam enhances inhibitory GABA-A signalling through benzodiazepine receptors. Its long action permits accumulation, especially in older people. Normal morning concentration and balance cannot be assumed. Mogadon: prescribing information.
Drowsiness, impaired alertness, memory changes and muscle effects can affect driving or machinery use. Do not drive when affected, and avoid alcohol because it worsens impairment. Ask the prescriber about your work and travel needs. A sufficient night’s sleep is not an automatic guarantee of safe driving. Accord: nitrazepam leaflet.
Explain whether you drive early, operate equipment, work shifts, care for someone overnight or need to get up frequently. These practical demands belong in the prescribing discussion. Do not transfer a waiting period from a zopiclone or zolpidem guide to nitrazepam: this article supplies no universal time after which driving is safe.
Insomnia care before a hypnotic: assessment, CBT and a review plan
Insomnia assessment considers stress, pain, medicines, substances, shift work and other sleep disorders. NHS describes CBT to address thoughts and behaviours that maintain insomnia. Sleeping tablets are generally reserved for short use when other measures have not helped and symptoms are severe. A tablet prescription does not replace assessment of the cause. NHS: insomnia assessment.
Loud snoring, gasping, witnessed pauses in breathing and marked daytime tiredness warrant assessment for sleep apnoea. A sleep study may be needed. NHS cautions that sleeping pills may worsen sleep apnoea unless recommended by the treating doctor; sedation should not be mistaken for treatment of obstructed breathing. NHS: sleep apnoea assessment.
At the first appointment, bring a record of sleep timing, daytime difficulty, medicines and substances used to sleep or stay awake. Agree what improvement would make treatment worthwhile, what adverse effects would trigger review and who to contact before the prescription runs out. Ask whether CBT-I or another suitable service is available locally.
Supplements and practical support: avoid adding a sedating sleep stack
NCCIH describes inconsistent insomnia findings for valerian and concerns about long-term safety. Kava has been associated with serious liver injury. The reviewed information does not establish a supplement that replaces insomnia assessment or makes nitrazepam safe. Adding a natural sleep product is a separate interaction and safety decision, not a proven way to lower withdrawal risk. NCCIH: sleep and complementary approaches.
Give the pharmacist the full names, ingredients and amounts of herbs and supplements already used, as well as products you plan to add. Supplement safety varies with health conditions, pregnancy and other medicines. A natural label or general wellness claim does not establish compatibility with a prescription sedative. NCCIH: supplement safety.
Medication review is part of assessing falls, alongside balance, strength, vision and the home environment. Discuss nighttime trips to the bathroom, poor lighting and obstacles. Following a fall, suspected head, neck, back or hip injury or inability to get up requires urgent emergency assistance; do not assume it is only a medicine effect. NHS: falls and medicine review.
Keep the medicine list somewhere a caregiver can find it. If someone notices a change in your alertness, walking or behaviour, include that observation at review. Practical support can reduce confusion about prescriptions, but it does not substitute for changing an unsafe treatment plan with the clinician.
What the evidence establishes: short trials and the January 2026 warning
An original 1991 abstract describes a small double-blind crossover study with short treatment periods. Its funding index identifies non-US-government support without settling the exact sponsor or supplied-drug chain. The full declarations were not obtained. Its positive results are therefore not used for an independent efficacy verdict, and its design cannot settle years-long use. Götestam et al.: 1991 trial abstract.
MHRA’s January 2026 review examined communication of addiction, dependence, tolerance and withdrawal risks. It considered prescribing records, spontaneous reports, licence-holder material and stakeholder input. It did not reassess each medicine’s efficacy, dose or indication, and excluded specialist uses such as epilepsy. A strengthened warning is not a new comparative trial or a blanket instruction to stop treatment. MHRA: 2026 warning review.
eMC’s process states that pharmaceutical companies draft information, regulators check it and companies publish the approved documents. Pharmaceutical subscriptions pay for publication. Approval helps explain the documents’ regulatory role; it does not turn maker-written outcome claims into independent research. eMC: publishing and payment process.
This guide separates clinical practice, regulatory safety information and financially cleared comparative benefit. No independent superiority claim is made over zopiclone, temazepam, melatonin or another hypnotic. An unresolved financial chain limits what can be concluded; it does not prove that a particular result is false.
Risks and urgent symptoms: sedation, overdose, allergy and behaviour changes
Drowsiness, dizziness, confusion, muscle weakness, poor coordination and double vision can occur. Tell the prescriber when symptoms affect ordinary activity or persist. Take the medicine only as directed, do not double a missed dose, and keep it out of children’s reach. Swallow tablets with water or another non-alcoholic drink according to the dispensing instructions. Mogadon: patient leaflet.
Seek immediate medical help for facial or throat swelling, breathing or swallowing difficulty, a severe blistering rash, jaundice, or suicidal thoughts or behaviour. Severe breathing difficulty, collapse or immediate danger requires emergency services. New agitation, aggression, hallucinations, nightmares or unusual behaviour needs prompt prescriber contact; do not simply add another sedative. Accord: nitrazepam leaflet.
Suspected benzodiazepine overdose requires emergency help immediately, including accidental extra intake or someone else taking the medicine. Tell responders the name, amount if known, timing and other substances. Physical dependence is distinct from addiction; neither concern is a reason to hide what was taken or delay help. MHRA: benzodiazepine patient resource.
Do not make someone vomit or give food, drink or a home antidote after suspected poisoning. Follow emergency instructions, keep the packaging and do not drive yourself. Unresponsiveness, seizures or breathing difficulty require immediate emergency action. Even if another document suggests vomiting, do not attempt it. NHS: poisoning emergency.
Interactions: opioids, alcohol, antihistamines, other sedatives and herbs
MHRA warns that combining benzodiazepines with opioids can cause profound sedation, breathing suppression, coma and death. A clinician may consider a combination only where alternatives are unsuitable and with close monitoring. Pain medicines, opioid-substitution treatment and some cough remedies can matter; disclose all of them rather than judging risk by whether the medicine was prescribed. MHRA: opioids and benzodiazepines.
Other sedatives, sedating antihistamines, muscle relaxants, sodium oxybate and anticonvulsants require review. Enzyme-altering medicines such as some antifungals, antibiotics and omeprazole can change benzodiazepine exposure; St John’s wort can also alter clearance. The label flags valerian as potentially changing nitrazepam’s effect. This list is incomplete. Accord: nitrazepam SmPC.
Tell every prescriber and pharmacist about nitrazepam before a new medicine, procedure or nonprescription sleep remedy is added. Use the exact active ingredients rather than the label “painkiller” or “allergy tablet.” If a combination causes severe sleepiness or abnormal breathing, urgent assessment takes priority over a routine interaction enquiry.
Who needs extra assessment: sleep apnoea, organ disease, pregnancy and breastfeeding
The reviewed tablet label contraindicates use in children, sleep apnoea, severe respiratory or liver insufficiency and myasthenia gravis. Kidney, liver or lung disease and older age can change susceptibility and require individual prescribing review. Tell the team about previous substance problems, psychiatric symptoms and allergies; this is not a self-screening checklist that makes use safe. Accord: nitrazepam SmPC.
Mogadon’s leaflet advises avoiding use during breastfeeding. Mogadon: patient leaflet.
SPS describes cautious specialist use with infant monitoring, but only for full-term healthy infants and with very limited evidence; prolonged exposure raises accumulation concerns. These sources serve different roles. Seek a prescribing/breastfeeding assessment, particularly for a premature or unwell infant. Do not bedshare with a baby while taking a sedating medicine. SPS: breastfeeding assessment.
Pregnancy or pregnancy plans need prompt prescriber advice. Late exposure can affect neonatal breathing, feeding or withdrawal. Do not independently stop an established prescription; arrange individual assessment of maternal and fetal risks. Accord: nitrazepam leaflet.
This guide does not establish a safe pregnancy dose, milk exposure threshold or infant monitoring timetable. An epilepsy prescription also needs its own specialist review; the adult-insomnia course limits here should not be copied into that setting.
Clinician-led use and stopping: course limits, missed doses and flexible withdrawal
NICE recommends an agreed plan and review, with withdrawal usually gradual and adapted to symptoms. Reductions can become smaller as the dose falls. New symptoms need assessment because withdrawal, the original condition and another illness can overlap. Do not abruptly stop except under appropriate medical direction for exceptional serious harm. CBT can be considered during benzodiazepine withdrawal. NICE NG215: withdrawal care.
The Scottish guide discusses long-acting nitrazepam and individual reduction options. Switching to another benzodiazepine is not automatic, and conversion tables are approximate. Withdrawal may be delayed with long-acting medicines; formulation, other medicines and health conditions matter. A published schedule is not a personalized taper or permission to alter tablets yourself. Scotland: tailored benzodiazepine reduction.
Withdrawal can include severe symptoms such as seizures. A seizure requires immediate emergency help; do not manage it by copying a home withdrawal protocol. MHRA: benzodiazepine patient resource.
Discuss a stopping strategy before treatment starts and revisit it during treatment. The January 2026 warning stresses that dependence, tolerance and withdrawal can occur during short prescribed use. If the effect seems weaker, do not increase the dose or supplement it yourself; contact the prescriber. Established withdrawal may take weeks or months and requires an adaptable plan. MHRA: January 2026 warning.
Mogadon’s leaflet describes usual short-term treatment of no more than four weeks; longer-term users can need a longer reduction period. This does not impose a four-week deadline on established withdrawal. Agree supply, review and supervision with the prescriber. Mogadon: patient leaflet.
Animal and laboratory evidence: mechanisms do not establish a personal regimen
The label describes animal reproductive hazards and species differences; human fertility data are lacking. These findings cannot establish an individual risk, safe pregnancy regimen or treatment benefit. Accord: nitrazepam SmPC.
Laboratory findings, drug concentrations, feeling sedated and restored daytime functioning are different outcomes. Ask which outcome supports a claim, which population was studied and whether dependence, falls and next-day performance were assessed. This article supplies no animal-derived human dose, self-directed benzodiazepine conversion or supplement withdrawal protocol.
Funding and source roles
Research funding at a glance
37 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| Mogadon: prescribing information | Viatris Products Limited, Potters Bar, is licence holder. Maker sales; corporate/eMC routes below. Product revenue unclosed. | United Kingdom; product-specific licence | Tier 4 — maker-produced; self-interest | D for independent efficacy. Text November 2025; eMC updated 17 February 2026. Regulatory safety role. |
| Mogadon: patient leaflet | Same maker route. Lists ICN Polfa Rzeszów, Poland, as manufacturer; this is not every nitrazepam product’s factory. | UK licence; Polish manufacture | Tier 4 — maker-produced; self-interest | D for independent efficacy. Six-page leaflet revised November 2025; safety context. |
| Accord: nitrazepam SmPC | Accord-UK Ltd, Barnstaple, licence holder; seller route below. Original supporting-study finances unclosed. | United Kingdom; product-specific licence | Tier 4 — maker-produced; self-interest | D for independent efficacy. Text 26 February 2026; posted 4 March. Regulatory safety context. |
| Accord: nitrazepam leaflet | Accord-UK maker/holder route below; regulator approval does not remove producer interests. | United Kingdom; product-specific licence | Tier 4 — maker-produced; self-interest | D for independent efficacy. Footer November 2025; portal approval 26 February 2026/posting 4 March. |
| MHRA: January 2026 warning | See MHRA’s own accounts below. Adviser contracts, warning allocation and original-study sponsors unclosed. | UK; MHRA, London | Tier 3 — regulator with industry-fee route; context | C provisional. 8 January 2026. Public safety mandate; fees do not prove a particular finding is biased. |
| MHRA: benzodiazepine patient resource | See MHRA’s own accounts below. Adviser contracts, warning allocation and original-study sponsors unclosed. | UK; MHRA, London | Tier 3 — regulator with industry-fee route; context | C provisional. Distributed with January 2026 update. Public safety mandate; fees do not prove a particular finding is biased. |
| MHRA: 2026 warning review | See MHRA’s own accounts below. Adviser contracts, warning allocation and original-study sponsors unclosed. | UK; MHRA, London | Tier 3 — regulator with industry-fee route; context | C provisional. 8 January 2026. Public safety mandate; fees do not prove a particular finding is biased. |
| MHRA: opioids and benzodiazepines | See MHRA’s own accounts below. Adviser contracts, warning allocation and original-study sponsors unclosed. | UK; MHRA, London | Tier 3 — regulator with industry-fee route; context | C provisional. 18 March 2020. Public safety mandate; fees do not prove a particular finding is biased. |
| NICE NG215: withdrawal care | See NICE accounts/membership below; committee interests and underlying trials unclosed. | England; NICE, Manchester/London | Tier 2 — public care guidance; provisional | C provisional. Published 20 April 2022; later MHRA link is not a new guideline date. |
| Scotland: tailored benzodiazepine reduction | Government institutional route/working group below; contributor and cited-trial finances unclosed. | Scotland, UK; Edinburgh | Tier 2 — public prescribing context; provisional | C provisional. 14 August 2024; approximate conversion tables are not personal instructions. |
| SPS: breastfeeding assessment | See SPS’s own commission disclosure below; no named page reviewer or trial finance cleared. | England, UK; multiprovider service | Tier 2 — professional safety context; provisional | C provisional. 15 February 2024; very limited evidence, full-term healthy infants only. |
| NHS: insomnia assessment | Dated national website process below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 19 March 2024. Public-service incentives; no cleared drug outcome. |
| NHS: poisoning emergency | Dated national website process below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 12 June 2025. Public-service incentives; no cleared drug outcome. |
| NHS: falls and medicine review | Dated national website process below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 6 March 2025. Public-service incentives; no cleared drug outcome. |
| NHS: sleep apnoea assessment | Dated national website process below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 11 May 2026. Public-service incentives; no cleared drug outcome. |
| NCCIH: sleep and complementary approaches | Dated fiscal route below. Credited NCCIH reviewers’ outside interests and original-study finances unclosed. | United States; Bethesda, Maryland | Tier 2 — public safety/uncertainty context | C provisional. May 2024. Public education; no independent product efficacy adopted. |
| NCCIH: supplement safety | See dated fiscal row; page/expert and original-study finance unclosed. | United States; Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. Footer January 2019 despite later references; date limit retained. |
| Götestam et al.: 1991 trial abstract | Non-US-government support indexed; exact funder, supplied drug, grants and personal interests not established. NLM hosting is not trial funding. | Norway; Ostmarka Hospital/University of Trondheim | Tier 2 — provisional; financial chain unknown | C provisional. Only original abstract/index read; full-paper declarations unclosed. Unknown is not independent or misconduct. |
| NHS national website content policy | Dated DHSC website funding; no ads/corporate sponsorship stated. Individual provider finances and current contracts unclosed. | England, United Kingdom; national website jurisdiction | Tier 3 — institutional financial/process self-report | B provisional process self-report. Reviewed 14 October 2022; October 2025 review due has passed. |
| NCCIH FY2025 congressional justification | NIH/HHS federal budget route; historical request, not current enactment. Gifts/page allocation unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional historical self-report. Page says it no longer reflects current HHS policy; budget-advocacy incentives. |
| NHSBSA: 2025/26 audited institutional accounts | DHSC sponsor/appointed board; main Parliamentary support plus full-cost service-contract income and public repayment work. Separate student-support routes. Specific PCA allocation and staff/contractor interests unknown. | United Kingdom; Stella House, Goldcrest Way, Newcastle upon Tyne | Tier 3 — institutional financial/identity self-report | B provisional. Report printed 13 July 2026. Accountability/service incentives; selected notes read, complete subsidiary/backer audit unclosed. |
| MHRA: 2025/26 audited accounts | Industry statutory/nonstatutory fees plus DHSC grant-in-aid and other service/research routes. Licence/vigilance fees document an industry relationship; warning/adviser allocation unknown. | UK; 10 South Colonnade, London | Tier 3 — institutional financial self-report | B provisional financial facts. Published 15 July 2026; selected audited notes, not full backer clearance. |
| NICE: 2025/26 accounts | DHSC/NHS England support, appraisal/advice fees, research/licences and other income. Exact NG215 allocation unknown. | UK; Manchester/London | Tier 3 — institutional financial self-report | B provisional selected financial facts. Current accounts cannot clear a 2022 committee. |
| NICE NG215: committee membership | NICE-appointed group; Margaret Lally chaired from January 2021, Cathy Stannard topic adviser. Named affiliations do not disclose payments. | UK; guideline committee | Tier 3 — institutional process self-report | B provisional membership facts. Full interests/contracts and original-trial funds remain unclosed. |
| Scotland: guideline working group | Government group chaired by Alastair Cook; deputy Alpana Mair. Provider/charity participation; individual contracts and trial sponsors unclosed. | Scotland, UK; Edinburgh | Tier 3 — institutional process self-report | B provisional identities. 14 August 2024; membership is not a financial declaration. |
| Scotland: public financial framework | Block grant, taxes and permitted borrowing public routes; exact prescribing-guide allocation unknown. | Scotland, UK; government jurisdiction | Tier 3 — institutional financial/process self-report | B provisional selected framework. Fiscal index does not clear NHS bodies or working-group interests. |
| Scotland: government identity | Government contact self-report; financial framework separate. Individual contributors not cleared. | UK; St Andrew’s House, Regent Road, Edinburgh | Tier 3 — institutional identity self-report | B provisional location facts. Updated 7 October 2024; service incentives. |
| SPS: own commissioning disclosure | NHS England commissioning of provider-trust contracts/subcontracts. Stated contracts end 31 March 2026; subsequent renewal and page allocation unverified. | England, UK; multiprovider network | Tier 3 — institutional funding/process self-report | B provisional dated disclosure. Current October 2026 arrangements and contributors’ interests unknown. |
| eMC: publishing and payment process | Datapharm owns/manages eMC; pharma subscriptions pay for publishing. Companies draft/publish regulator-approved labels; complete ultimate-owner chain unclosed. | UK; Cassini Court, Randalls Way, Leatherhead | Tier 4 — paid maker publishing channel | B provisional process facts; D for independent efficacy. Paid-publication incentives persist after regulatory review. |
| Viatris: 2025 corporate filing | Medicines sales, listed equity and borrowing; complete beneficial-owner chain and Mogadon receipts unclosed. | US; Delaware registrant, Canonsburg, Pennsylvania HQ | Tier 4 — seller financial self-report | B provisional selected financial facts; D efficacy. Year ended 31 December 2025, filed February 2026; investor incentives. |
| Accord: product identity and update | Seller-maintained portal; Accord-UK licence holder, Whiddon Valley, Barnstaple. Product allocation unclosed. | UK; Barnstaple licence holder | Tier 4 — maker product/process record | B provisional identity/date facts; D efficacy. Posted 4 March 2026; approval 26 February distinct from PIL footer. |
| Accord: 2025 business-route disclosure | Accord Healthcare/Accord-UK develop, manufacture and sell medicines; suppliers purchase inputs. Product-specific receipts and financing not disclosed here. | UK; named companies separate from Indian parent | Tier 4 — seller business self-report | B provisional route facts; D efficacy. Statement September 2025/FY March 2025; reputational incentives. |
| Accord: stated Intas relationship | Accord describes itself as Intas Pharmaceuticals’ international arm. Current ultimate shareholders and nitrazepam funding allocation unclosed. | UK; Accord Healthcare registered North Harrow; Intas parent, India | Tier 4 — seller ownership self-report | B provisional relationship; D efficacy. Revised November 2024; no verified present share percentage. |
| Intas: investor index and identity | Parent investor index offers dated annual-return and governance links. Complete current shareholdings, borrowing and nitrazepam allocation unclosed. | India; corporate office, Thaltej, Ahmedabad | Tier 4 — seller financial/identity index | B provisional index/location facts; D efficacy. FY2022/2023 return links are not a current ownership audit. |
| NHSBSA: 2025/26 prescribing publication | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: nitrazepam item count | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: prescribing methodology | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 3 — institutional method self-report | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
Frequently asked questions
Is nitrazepam the same as zopiclone? No. Nitrazepam is a benzodiazepine; do not transfer zopiclone instructions to it. Mogadon: prescribing information.
Does nitrazepam cure the cause of insomnia? A hypnotic does not replace assessment of pain, stress, medicines or another sleep disorder; discuss the cause and suitable care. NHS: insomnia assessment.
Can dependence happen while taking the prescribed dose? Yes, even short recommended use can cause dependence or withdrawal; discuss concerns without independently increasing or stopping it. MHRA: January 2026 warning.
Can I suddenly stop nitrazepam? Do not stop an established prescription abruptly or copy a taper. The clinician should assess symptoms and plan an individual reduction. NICE NG215: withdrawal care.
Is nitrazepam automatically safe during breastfeeding? No. The limited SPS context applies to selected healthy full-term infants and requires individual professional assessment, not blanket permission. SPS: breastfeeding assessment.
What should I do after suspected nitrazepam overdose? Get immediate emergency help. Do not wait for severe symptoms, share medicine or attempt a home antidote. MHRA: benzodiazepine patient resource.
Sources and funding notes
Reviewed 4 October 2026. Dedicated adult nitrazepam insomnia guide; product-specific UK tablet sources do not close worldwide licensing or specialist epilepsy care. Manufacturer-issued labels are Tier 4/D for independent efficacy; regulatory safety roles are separate. MHRA’s documented institutional industry-fee route is not proof that a particular warning was sponsor-directed. Public pages and memberships do not clear individual contracts or underlying trials. The warning review did not reassess efficacy or dose. Portal posting, approval and leaflet-text dates are distinguished; dated commissioning and policy gaps remain explicit. No personal dose, forced taper, universal driving interval or complementary replacement is supplied. Whole-source budgets charge complete linked paragraphs, FAQs, profiles/references and evidence/notes/metadata repetitions.
- Mogadon: prescribing information — Indication, mechanism and persistence; efficacy/dose claims excluded.
- Mogadon: patient leaflet — Common effects, handling, course limits and breastfeeding caution.
- Accord: nitrazepam SmPC — Contraindications and interactions; overdose-emesis instruction excluded.
- Accord: nitrazepam leaflet — Pregnancy, driving and urgent adverse effects.
- MHRA: January 2026 warning — Dependence, tolerance and individual withdrawal care.
- MHRA: benzodiazepine patient resource — Overdose emergency, no sharing and dependence distinction.
- MHRA: 2026 warning review — Warning-method scope, not efficacy reassessment.
- MHRA: opioids and benzodiazepines — Potentially fatal additive respiratory depression.
- NICE NG215: withdrawal care — Shared review, symptom assessment and adaptable withdrawal.
- Scotland: tailored benzodiazepine reduction — Long action, delayed withdrawal and individual formulation review.
- SPS: breastfeeding assessment — Label-versus-specialist assessment and infant safety.
- NHS: insomnia assessment — Underlying causes and CBT context; no comparative efficacy estimate.
- NHS: poisoning emergency — Emergency response; never induce vomiting.
- NHS: falls and medicine review — Falls assessment, home hazards and urgent injury care.
- NHS: sleep apnoea assessment — Breathing symptoms, testing and sleeping-pill caution.
- NCCIH: sleep and complementary approaches — Valerian uncertainty, kava hazard and no substitute claim.
- NCCIH: supplement safety — Full ingredient disclosure and interaction uncertainty.
- Götestam et al.: 1991 trial abstract — Historical short-trial design only; positive outcomes excluded.
- NHS national website content policy — National website policy, not provider or trial finance.
- NCCIH FY2025 congressional justification — Institutional route only; no present appropriation or product efficacy.
- NHSBSA: 2025/26 audited institutional accounts — Institutional finance only; no drug efficacy, item accuracy or maker influence inferred.
- MHRA: 2025/26 audited accounts — Agency finance only; no maker sponsorship of a specific conclusion inferred.
- NICE: 2025/26 accounts — Institutional income only; guideline/trial interests separate.
- NICE NG215: committee membership — Identities only, not financial independence clearance.
- Scotland: guideline working group — Named contributor roles only.
- Scotland: public financial framework — Government finance context only.
- Scotland: government identity — Publisher location, not study-country proof.
- SPS: own commissioning disclosure — SPS-specific route; national NHS website policy not substituted.
- eMC: publishing and payment process — Label provenance only, not neutral trial evidence.
- Viatris: 2025 corporate filing — Corporate route only; UK licence holder separate.
- Accord: product identity and update — Source version and licence only.
- Accord: 2025 business-route disclosure — Sales route only; no supply-chain quality conclusion.
- Accord: stated Intas relationship — Stated corporate relationship only.
- Intas: investor index and identity — Parent identity/access limits only.
- NHSBSA: 2025/26 prescribing publication — Date and scope, not worldwide popularity.
- NHSBSA: nitrazepam item count — English community items only, not patients or insomnia-only use.
- NHSBSA: prescribing methodology — Community versus hospital scope and item definition.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.